NEW YORK (AP) -- Johnson & Johnson said Monday that the regulators in the U.S. and Europe have expanded the approval of its psoriasis drug Stelara, allowing the company to market Stelara as a treatment for psoriatic arthritis in adults.

Psoriatic arthritis is a form of arthritis that causes joint pain, stiffness and swelling in patients with psoriasis.

The Food and Drug Administration approved Stelara in 2009 as a treatment for psoriasis. Revenue from the drug rose 50 percent to $371 million in the second quarter. The company said Monday that the Food and Drug Administration and European Commission both granted additional marketing approvals. That could increase sales of Stelara.

European regulators also cleared Johnson & Johnson's drug Simponi as a treatment for ulcerative colitis, an inflammatory bowel disease. Worldwide sales of Simponi, which also treats rheumatoid arthritis, rose 40 percent to $175 million during the second quarter.

Johnson & Johnson makes drugs, medical devices from bandages to surgical products, and over-the-counter medicines including Tylenol and Motrin. The company's overall revenue grew 8.5 percent to $17.88 billion in the second quarter.

Shares of the New Brunswick, N.J., company slipped 70 cents to $88.98 in midday trading.